At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
Myrcludex B +2 moredrug
Likely dose
Tenofovir 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Randomised, Comparative, Parallel-Arm, Phase II Study to Assess Efficacy and Safety of Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent
In Brief
A Phase 2 clinical trial evaluating Myrcludex B, PEG IFN alfa-2a, and 1 other intervention for Chronic Viral Hepatitis B With Delta-agent. Completed, enrolled 90 participants across 7 sites.
Detailed Summary
Randomised, Comparative, Parallel-Arm Study to Assess Efficacy and Safety of Myrcludex B in Combination with Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients with Chronic Viral Hepatitis B with Delta-agent
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesRussia
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedSep 2016
Primary CompletionNov 2019
Study CompletionOct 2020
TodayJul 2026
First PostedSep 2, 2016
Enrollment StartApr 1, 2016
Primary CompletionNov 22, 2019
Study CompletionOct 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.8 years ago
Interventions
Myrcludex Bdrug
Lyophilised powder for solution for subcutaneous injection
PEG IFN alfa-2adrug
solution for subcutaneous injection, once per week
Tenofovirdrug
Film-coated tablets, 300 mg, per os, once daily